January 2026

Oncology advances in 2025 highlight transformative therapies and the vital role of pharmacists in enhancing patient care and treatment outcomes.

Pivotal FDA approvals in breast cancer treatment focused on precision medicine and innovative therapies in 2025.

Experts explore the evolving role of HER2- and TROP2-targeted therapies in breast cancer treatment at SABCS 2025, highlighting ADC advancements.

Latest findings presented at SABCS 2025 support trastuzumab deruxtecan's effectiveness and safety in treating HER2-positive breast cancer.

Tucatinib enhances first-line maintenance therapy for HER2-positive metastatic breast cancer, improving progression-free survival and safety outcomes, as shown in the HER2CLIMB-05 trial.

Oral SERDs and combination therapies are redefining post-CDK4/6 treatment in HR+/HER2– metastatic breast cancer.

Exploratory analysis shows 1 in 4 patients maintain a long-term response to ribociclib.

Teclistamab combined with daratumumab and hyaluronidase shows significant efficacy in relapsed multiple myeloma, potentially redefining treatment standards.

New long-term data reveal avapritinib's impressive efficacy and safety in advanced systemic mastocytosis.

Explore the advancements and challenges of allogeneic CAR T-cell therapies, including immune rejection and innovative engineering strategies for cancer treatment.

The Isa-VRd regimen shows consistent efficacy results across all age and frailty levels in patients with newly diagnosed multiple myeloma.

Pharmacists enhance multiple myeloma care by managing cytokine release syndrome and advocating for safe vaccination strategies at ASH 2025.

Experts at the ASH Annual Meeting and Exposition in Orlando, Florida, explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.